Physician profile
Christopher Vivas
NPI 1972850154
$1,262.18
in general payments reported to CMS, 2019-2025
14 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.52 · 2021: $73.29 · 2022: $522 · 2023: $393 · 2024: $50.57 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $451.96 | 2022-2025 | Trelegy Ellipta |
| Amgen INC. | $178.67 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $120.54 | 2023-2024 | |
| Lilly USA, LLC | $99.31 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $92.41 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.22 | 2022-2023 | Ofev |
| Novartis Pharmaceuticals Corporation | $60.62 | 2022 | |
| Daiichi Sankyo INC. | $36.81 | 2020-2021 | |
| Alkermes, INC. | $29.32 | 2025 | Vivitrol |
| Novo Nordisk INC | $28.97 | 2022-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $23.87 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $19.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.29 | 2022 | |
| Astellas Pharma US INC | $16.61 | 2024 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.